UBS Group
KRYS icon

UBS Group’s Krystal Biotech KRYS Stock Holding History

UBS Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.2M Sell
11,300
-4,800
-30% -$1.43M ﹤0.01% 4354
2026
Q1 		$4.16M Buy
+16,100
New +$4.28M ﹤0.01% 4261
2025
Q4 		– Sell
-148,500
Closed -$26.2M – 10886
2025
Q3 		$26.2M Buy
148,500
+96,300
+184% +$14.4M ﹤0.01% 2267
2025
Q2 		$7.18M Buy
+52,200
New +$7.67M ﹤0.01% 3482

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UBS Group's KRYS Position: Q2 2026 in Review

UBS Group increased its Krystal Biotech (KRYS) stake by 3.3% in Q2 2026, buying an estimated $1.43M and bringing the position to 148,316 shares worth $55.1M. The position accounts for 0.01% of the portfolio, ranked #1646.

UBS Group first reported a position in KRYS in Q3 2017 and has held it in 30 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • UBS Group held 148,316 shares of Krystal Biotech worth $55.1M as of Q2 2026.
  • UBS Group bought 4,791 Krystal Biotech shares in Q2 2026, an estimated $1.43M.
  • Krystal Biotech made up 0.01% of UBS Group's portfolio in Q2 2026, its #1646 holding.
  • UBS Group first reported a position in Krystal Biotech in Q3 2017 and has held it in 30 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.